MedTrace Logo

Safety and Efficacy Study of 90Y-hPAM4 at Different Doses

NCT00597129 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2021-08-19

No results posted yet for this study

Summary

Safety study to determine highest dose of 90Y-hPAM4 can be safety administered

Conditions

Interventions

BIOLOGICAL

90Y-hPAM4

Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.

Sponsors & Collaborators

Principal Investigators

  • William Wegener, MD, PhD · Gilead Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00597129 on ClinicalTrials.gov